[go: up one dir, main page]

FI960750L - Hermon kasvutekijän farmaseuttiset formulaatiot - Google Patents

Hermon kasvutekijän farmaseuttiset formulaatiot Download PDF

Info

Publication number
FI960750L
FI960750L FI960750A FI960750A FI960750L FI 960750 L FI960750 L FI 960750L FI 960750 A FI960750 A FI 960750A FI 960750 A FI960750 A FI 960750A FI 960750 L FI960750 L FI 960750L
Authority
FI
Finland
Prior art keywords
growth factor
pharmaceutical formulations
nerve growth
nerve
formulations
Prior art date
Application number
FI960750A
Other languages
English (en)
Swedish (sv)
Other versions
FI960750A0 (fi
FI113241B (fi
Inventor
Victoria M Knepp
Deborah M Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI960750A0 publication Critical patent/FI960750A0/fi
Publication of FI960750L publication Critical patent/FI960750L/fi
Application granted granted Critical
Publication of FI113241B publication Critical patent/FI113241B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI960750A 1993-08-20 1996-02-19 Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi FI113241B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10979893 1993-08-20
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor
US9409245 1994-08-16

Publications (3)

Publication Number Publication Date
FI960750A0 FI960750A0 (fi) 1996-02-19
FI960750L true FI960750L (fi) 1996-02-20
FI113241B FI113241B (fi) 2004-03-31

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960750A FI113241B (fi) 1993-08-20 1996-02-19 Menetelmä hermon kasvutekijän stabiloimiseksi ja pitkäaikaiseksi varastoimiseksi

Country Status (31)

Country Link
US (2) US6277828B1 (fi)
EP (1) EP0721343B1 (fi)
JP (2) JP4592830B2 (fi)
KR (1) KR100341193B1 (fi)
CN (1) CN1163265C (fi)
AT (1) ATE226085T1 (fi)
AU (1) AU677699B2 (fi)
BG (1) BG62951B1 (fi)
BR (1) BR9407278A (fi)
CA (1) CA2169834C (fi)
CZ (1) CZ292422B6 (fi)
DE (1) DE69431562T2 (fi)
DK (1) DK0721343T3 (fi)
ES (1) ES2181723T3 (fi)
FI (1) FI113241B (fi)
HU (1) HU228152B1 (fi)
IL (3) IL124941A (fi)
LT (1) LT4051B (fi)
LV (1) LV11279B (fi)
NO (1) NO317627B1 (fi)
NZ (1) NZ271873A (fi)
PL (1) PL176387B1 (fi)
PT (1) PT721343E (fi)
RO (1) RO114742B1 (fi)
RU (1) RU2126265C1 (fi)
SI (1) SI9420048B (fi)
SK (1) SK284064B6 (fi)
TW (1) TW427905B (fi)
UA (1) UA43348C2 (fi)
WO (1) WO1995005845A1 (fi)
ZA (1) ZA946333B (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
JP2001506226A (ja) * 1995-05-12 2001-05-15 ザ ロックフェラー ユニヴァーシティ シナプシンのモジュレーションによるアルツハイマー病の治療法
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
KR100497087B1 (ko) * 1995-11-07 2005-09-09 제넨테크, 인코포레이티드 신경성장인자의안정화조성물
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
EP1015826A2 (en) * 1996-05-29 2000-07-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
CA2289040A1 (en) * 1997-05-01 1998-11-05 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
WO1999016460A2 (en) * 1997-09-30 1999-04-08 Duke University Apolipoprotein e/growth factor complexes and methods of use
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
CN1607958A (zh) * 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
WO2004000347A1 (en) 2002-06-21 2003-12-31 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
EP1605968A2 (en) * 2003-03-18 2005-12-21 Novo Nordisk Health Care AG Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE454900T1 (de) * 2003-05-23 2010-01-15 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2008020584A1 (en) * 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
JP4111995B1 (ja) * 2006-11-08 2008-07-02 株式会社メディカル・アプライアンス 神経栄養因子産生促進装置
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
EP2349338A2 (fr) * 2008-09-26 2011-08-03 Adocia Complexe constitue d'un polysaccharide et d'une hpb
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
CA2832260C (en) 2011-04-07 2021-06-22 Neovacs Method for treating ifnalpha related conditions
BR112014019576A8 (pt) * 2012-02-08 2017-07-11 Agronomique Inst Nat Rech Fator de crescimento de nervos beta, composição farmacêutica e método para induzir a ovulação
CN107660149B (zh) * 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物及注射粉剂
ES2893239T3 (es) * 2015-04-21 2022-02-08 Staidson Beijing Biopharmaceuticals Co Ltd Composición de factor de crecimiento nervioso y polvo de inyección
CN107708723B (zh) * 2015-04-21 2021-04-13 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物和注射粉剂
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
US20200299371A1 (en) 2016-03-25 2020-09-24 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
MX388814B (es) * 2016-06-01 2025-03-20 Servier Ip Uk Ltd Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packages comprising polypropylene containers and ngf aqueous formulations packaged therein
EP4497431A1 (en) * 2023-07-27 2025-01-29 Dompé farmaceutici S.p.A. Pharmaceutical formulation comprising nerve growth factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
US5169834A (en) * 1990-11-30 1992-12-08 American Cyanamid Company Compositions and method for reducing vial breakage during lyophilization
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
KR100341193B1 (ko) 2002-06-21
WO1995005845A1 (en) 1995-03-02
IL124941A0 (en) 1999-01-26
NO317627B1 (no) 2004-11-29
SK284064B6 (sk) 2004-09-08
LV11279A (lv) 1996-06-20
HK1012990A1 (en) 1999-08-13
CZ292422B6 (cs) 2003-09-17
IL110725A0 (en) 1994-11-11
SI9420048A (en) 1996-10-31
BG62951B1 (bg) 2000-12-29
SI9420048B (sl) 2003-12-31
ATE226085T1 (de) 2002-11-15
LT96011A (en) 1996-07-25
RU2126265C1 (ru) 1999-02-20
ES2181723T3 (es) 2003-03-01
AU677699B2 (en) 1997-05-01
BG100371A (bg) 1996-12-31
PL176387B1 (pl) 1999-05-31
PT721343E (pt) 2003-01-31
IL110725A (en) 2004-09-27
DE69431562T2 (de) 2003-06-18
NO960651L (no) 1996-02-19
CN1163265C (zh) 2004-08-25
JPH10508000A (ja) 1998-08-04
ZA946333B (en) 1996-02-19
EP0721343A1 (en) 1996-07-17
DK0721343T3 (da) 2003-02-17
DE69431562D1 (de) 2002-11-21
EP0721343B1 (en) 2002-10-16
CA2169834A1 (en) 1995-03-02
US20010007662A1 (en) 2001-07-12
HUT74728A (en) 1997-02-28
TW427905B (en) 2001-04-01
NZ271873A (en) 1996-10-28
IL124941A (en) 2006-12-10
PL313084A1 (en) 1996-05-27
BR9407278A (pt) 1996-10-01
UA43348C2 (uk) 2001-12-17
CA2169834C (en) 2008-11-04
CZ42496A3 (en) 1996-05-15
JP2007314572A (ja) 2007-12-06
FI960750A0 (fi) 1996-02-19
AU7566894A (en) 1995-03-21
US7074763B2 (en) 2006-07-11
LV11279B (en) 1996-10-20
SK18396A3 (en) 1996-10-02
HU9600371D0 (en) 1996-04-29
US6277828B1 (en) 2001-08-21
HU228152B1 (en) 2012-12-28
JP4592830B2 (ja) 2010-12-08
RO114742B1 (ro) 1999-07-30
CN1133012A (zh) 1996-10-09
NO960651D0 (no) 1996-02-19
FI113241B (fi) 2004-03-31
LT4051B (en) 1996-10-25

Similar Documents

Publication Publication Date Title
FI960750L (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
HUP9601698A3 (en) Pharmaceutical composition of adiabetical activity
DE10199046I2 (de) Rapamycin-Zubereitungen zur oralen Verabreichung
PT589843E (pt) Composicoes farmaceuticas contendo ciclosporinas
EP0727217A3 (en) Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient
ITMI931306A1 (it) Procedimento microbico per la preparazione di mevinolina
FI961521L (fi) Lääkeformulaatioiden valmistusmenetelmä
ITMI921123A0 (it) Formulazioni farmaceutiche orali contenenti antocianosidi
FI945780A7 (fi) Uudet biologisesti aktiiviset eburnameniinijohdannaiset, niitä sisältävät farmaseuttiset koostumukset ja menetelmä niiden valmistamiseksi
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ZA933426B (en) New dihydroxybenzylamine derivatives their preparation and pharmaceutical compositions which contain them
AU3407597A (en) Useful formulations of acid addition salt drugs
AU6527390A (en) Pharmaceutical compositions for the treatment of ataxy and equilibrium problems
AU5560694A (en) Pharmaceutical formulations of ibuprofen
GB9201639D0 (en) Pharmaceutical formulations
HRP940315A2 (en) Process for the preparation of pharmaceutical compositions containinbg active ingredient
BR9307182A (pt) Composições farmacêuticas de 2-oxindol-1-carboxamidas 3-substituídas
GB9304745D0 (en) Use of pharmaceutical formulations
IT1277117B1 (it) Composizioni farmaceutiche per il trattamento delle ipercolesterolemie
EE9400182A (et) Peptiidühendid, nende kasutamine, valmistamismeetod ja farmatseutiline segu
FI973277A0 (fi) Farmaseuttisia valmisteita TNF:n estämiseksi
ITMI922181A0 (it) Procedimento per la preparazione di perfluoro-2-metil-4-metossipentano
EE03101B1 (et) Peptiidühendid, nende kasutamine, valmistamismeetod ja farmatseutiline kompositsioon
AU1290892A (en) Cosmetic or pharmaceutical preparation
GB9222849D0 (en) Novel use of pharmaceutical compositions

Legal Events

Date Code Title Description
MA Patent expired